Fluzone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
A 5cc vial of Fluzone

Fluzone is the commercial name of an influenza virus vaccine, distributed by Sanofi Pasteur. It is a split-virus vaccine that is produced by chemical disruption of the influenza virus. Therefore, it is incapable of causing influenza.

History[edit]

Fluzone is typically administered in a single dose by intramuscular injection;[1] an intradermal injection is also available.[2] It is presented as a 0.25 ml syringe for pediatric use, as a 0.5 ml syringe for adults and children, as a 0.5 ml vial for adults and children, and as a 5 ml vial for adults and children.[1] Fluzone must be refrigerated under temperatures from 2 to 8 °C (36 to 46 °F) and is inactivated by freezing. Fluzone was initially approved in 1980 by the FDA.[1]

Fluzone comes in three versions that are thimerosal-free. There is a 0.25 ml prefilled pediatric syringe, a 0.5 ml prefilled syringe, and a 0.5 ml vial. Thimerosal is used only in the 5 ml multi-use vial.[1]

The use of Fluzone in infants less than six months of age is not recommended. Immunization with Fluzone may not protect 100% of susceptible individuals.

In January 2011 the FDA recognized that 36 children from 6–24 months old had fevers and seizures within a day of the fluzone vaccine.[3]

Adverse effects[edit]

The following adverse effects have been reported:[1]

High-dose vaccine[edit]

A high-dose vaccine (Fluzone High-Dose) 4x the strength of standard flu vaccine was approved by the FDA in 2009.[4][5] This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine. According to the CDC,[6] "a study published in the New England Journal of Medicine[7] [in August, 2014] indicated that the high-dose vaccine was 24.2% more effective in preventing flu in adults 65 years of age and older relative to a standard-dose vaccine." CDC recommends the high-dose vaccine for people 65 and over but expresses no preference between it and standard vaccine. Further studies are underway.

References[edit]

External links[edit]